Latest Regentis Biomaterials News & Updates

See the latest news and media coverage for Regentis Biomaterials. We track all announcements, press releases, and industry mentions in real time, all in one place.

Regentis Biomaterials

Regenerative medicine company developing hydrogel implants for orthopedic tissue repair

regentis.co.il

Headquarters: Herzliya, Israel
Company type: Public company
Number of employees: 11–50
Industry: Biotechnology & Medical Research

Last updated October 22

Latest news about Regentis Biomaterials

In short: Regentis Biomaterials advanced GelrinC's U.S. Phase III trial, European commercialization, and scaled manufacturing with new patents.

Company announcements

October 22 Regentis Biomaterials

Regentis highlights GelrinC durability for cartilage repair

The hydrogel implant achieves CE mark in Europe. Regentis advances U.S. Phase III trials with superior pain relief and tissue regeneration data.

October 1 Regentis Biomaterials

Regentis Biomaterials accelerates U.S. trial enrollment

The company is opening new and existing clinical sites to finish patient enrollment by year-end for its pivotal study.

September 15 Regentis Biomaterials

Regentis Biomaterials approves solvent-free GelrinC process

European regulatory approval boosts yield by 400%, enabling scaling for commercial demand.

May 18 Regentis Biomaterials

Regentis Biomaterials develops and patents new manufacturing process

The solvent-free process increases GelrinC production yield by 400%.

Media coverage

September 11 USA Today

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year...

September 11 Becker's Spine Review

Regentis advances pivotal knee cartilage implant trial

Regentis Biomaterials has treated 43 of 80 patients in its pivotal U.S. trial evaluating GelrinC, a hydrogel implant for focal articular knee cartilage injuries. The...

August 27 Yahoo Finance

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart...

August 17 USA Today

Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A...

Never miss news about Regentis Biomaterials

Track Regentis Biomaterials and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Regentis Biomaterials competitors & trending companies

Browse news for competitors to Regentis Biomaterials and other trending companies.